Novita AI

elsewhere's corpus does not genuinely cover Novita AI as a subject. The retrieved material actually concerns **Novita (诺维药业 / Novita Pharmaceuticals)**, a US-based early-stage oncology drug company in FreeS Fund's portfolio that was developing what FreeS described as "the world's first anti-cancer drug to prevent cancer metastasis entering clinical stages" as of 2019 . FreeS Fund invested in Novita's angel round in the US in 2021 , alongside other small-molecule and innovative drug bets .

The entity card labeled "Novita AI" appears to be a misclassification — none of the retrieved chunks describe an AI company by this name. The "AI" suffix may stem from the unrelated Novita AI that appears in the entity cards , but the actual cited documents are about a pharmaceutical firm. Related coverage in elsewhere's corpus touches on other "Nova"-named entities (Nova Fusion, a fusion energy company ; Novasilicon, a chip-design startup ), but these are distinct companies and not usable as facts about Novita.